The U.S. FDA has pulled authorization for Eli Lilly and Co’s COVID-19 drug bebtelovimab, citing it is not expected to neutralize the dominant BQ.1 and BQ.1.1 subvariants of Omicron.   In February, the FDA issued Emergency Use Authorization for bebtelovimab, a monoclonal antibody treatment that demonstrated neutralization against the Omicron variant.   The data supporting this EUA were primarily based on analyses demonstrating that bebtelovimab retains full neutralizing activity against...